ArticleBiophysical journal2002
Structure of the 1-36 N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17.
Article in Biophysical journal, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- NMR structures of membrane proteins in phospholipid bilayers.Quarterly reviews of biophysics · 2014Review
- Structural dynamics and topology of phosphorylated phospholamban homopentamer reveal its role in the regulation of calcium transport.Structure (London, England : 1993) · 2013Article
- Phosphorylation and mutation of phospholamban alter physical interactions with the sarcoplasmic reticulum calcium pump.Journal of molecular biology · 2011Article
- Effects of PKA phosphorylation on the conformation of the Na,K-ATPase regulatory protein FXYD1.Biochimica et biophysica acta · 2009Article
- Structural constraints on the transmembrane and juxtamembrane regions of the phospholamban pentamer in membrane bilayers: Gln29 and Leu52.Biochimica et biophysica acta · 2007Article
- The alpha-helical propensity of the cytoplasmic domain of phospholamban: a molecular dynamics simulation of the effect of phosphorylation and mutation.Biophysical journal · 2005Article
- High-yield expression of isotopically labeled peptides for use in NMR studies.Protein science : a publication of the Protein Society · 2003Article
- Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis.Cellular and molecular neurobiologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The structure of a 36-amino-acid-long N-terminal fragment of human phospholamban phosphorylated at Ser-16 and Thr-17 and Cys-36-->Ser mutated was determined from nuclear magnetic resonance data in aqueous solution containing 30% trifluoroethanol. The peptide assumes a conformation characterized by two alpha-helices connected by an irregular strand, which comprises the amino acids from Arg-13 to Pro-21. The proline is in a trans conformation. The two phosphate groups on Ser-16 and Thr-17 are shown to interact preferably with the side chains of Arg-14 and Arg-13, respectively. The helix comprising amino acids 22 to 35 is well determined (the rmsd for the backbone atoms, calculated for a family of 24 nuclear magnetic resonance structures is 0.69 +/- 0.28 A). The structures of phosphorylated and unphosphorylated phospholamban are compared, and the effect of the two phosphate groups on the relative spatial position of the two helices is examined. The packing parameters Omega (interhelical angle) and d (minimal interhelical distance) are calculated: in the case of the phosphorylated phospholamban, Omega = 100 +/- 35 degrees and d = 7.9 +/- 4.6 A, whereas for the unphosphorylated peptide the values are Omega = 80 +/- 20 degrees and d = 7.0 +/- 4.0 A. We conclude that 1) the phosphorylation does not affect the structure of the C terminus between residues 21 and 36 and 2) the phosphorylated phospholamban has more loose helical packing than the nonphosphorylated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.